

Evaluation of Immunohistochemical HIF-1 α Expression in Gastric Adenocarcinomas According to Clinicopathological Parameters

Mide Adenokarsinomlarında İmmünohistokimyasal HIF-1α Ekspresyonunun Klinikopatolojik Parametrelerle İlişkisinin Değerlendirilmesi

🕲 Talya Akata¹, 🕲 Gülden Diniz², 🕲 Pınar Öksüz³, 🕲 Yetkin Koca4, 🕲 Samir Abdullazade⁵

¹University of Health Sciences Türkiye, İzmir Suat Seren Chest Diseases Hospital, Clinic of Pathology, İzmir, Türkiye ²İzmir Democracy University, Buca Seyfi Demirsoy Research Hospital, Clinic of Pathology, İzmir, Türkiye ³Ankara Bilkent City Hospital, Clinic of Pathology, Ankara, Türkiye ⁴Malatya Forensic Medicine Institution, Department of Pathology, Malatya, Türkiye ⁵Christian-Albrechts-University, University Hospital Schleswig-Holstein, Clinic of Pathology, Kiel, Germany

Cite as: Akata T, Diniz G, Öksüz P, Koca Y, Abdullazade S. Evaluation of immunohistochemical HIF-1α expression in gastric adenocarcinomas according to clinicopathological parameters. Anatol J Gen Med Res. 2025;35(1):65-73

Abstract

Objective: The alpha subunit of hypoxia-inducible factor-1 (HIF-1 α) activates glucose transport, glycolytic enzymes, and transcription of genes encoding vascular endothelial growth factor (VEGF). HIF-1 α expression is a mechanism by which tumor cells adapt to hypoxia. Gastric cancer is one of the most common cancers world-wide and has the highest mortality rate. Because patients are usually in their advanced stages at the time of diagnosis, the survival rates are low. The present study aimed to evaluate the prognostic significance of tissue expression of HIF-1 α in gastric adenocarcinomas.

Methods: In this study, immunohistochemical HIF-1 α expression was analyzed in gastrectomy materials from 114 gastric adenocarcinomas.

Results: HIF-1 α expression was detected in 24 cases (21.1%). One (p=0.02) and five-year (p=0.03) survival rates were higher in cases with HIF-1 α expression. In the regression analysis, the risk of death was 3.42 times higher in patients with advanced pathologic tumor stages (pT3 and pT4). Age, sex, tumor size, tumor location, lymphovascular and perineural invasion, human epidermal growth factor receptor 2 expression, and other clinicopathological parameters were not significantly correlated with HIF-1 α expression and survival.

Conclusion: It is important to identify specific prognostic markers and new targeted treatment options for gastric cancer. Despite conflicting findings, HIF-1 α expression is recognized as a negative prognostic factor in many malignancies, and therapeutic agents that may be effective, especially in the HIF-1 α /VEGF pathway, have been developed. However, the survival rate of patients with HIF-1 expression was higher in patients with HIF-1 α expression. A greater amount of data should be retrieved from further research studies on the prognostic significance of HIF-1 α expression in gastric carcinomas, especially after the standardization of immunohistochemical evaluation methods of its expression.

Keywords: Stomach, gastric carcinoma, HIF-1a, HER2



Address for Correspondence/Yazışma Adresi: Gülden Diniz Prof. MD, İzmir Democracy University, Buca Seyfi Demirsoy Research Hospital, Clinic of Pathology, İzmir, Türkiye E-mail: gulden.diniz@idu.edu.tr ORCID ID: orcid.org/0000-0003-1512-7584

Received/Geliş tarihi: 29.03.2024 Accepted/Kabul tarihi: 20.06.2024 Epub: 29.04.2025 Published date/Yayınlanma tarihi: 15.05.2025

0

Copyright© 2025 The Author. Published by Galenos Publishing House on behalf of University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital. This is an open access article under the Creative Commons AttributionNonCommercial 4.0 International (CC BY-NC 4.0) License.

Öz

Amaç: Hipoksi ile indüklenen faktör-alfa alt ünitesinin (HIF-1α) aktivasyonuyla glukoz transportunu, glikolitik enzimleri ve vasküler endotelyal büyüme faktörü (VEGF) kodlayan genlerin transkripsiyonunu aktive eder. HIF-1α ekspresyonunun tümör hücrelerinin hipoksiye adaptasyon mekanizmalarından biri olduğu gösterilmiştir. Mide kanserleri dünyada en sık görülen ve mortalitesi en yüksek kanserler arasında yer almaktadır. Tanı anında genellikle ileri evrede olduğu için sağkalım oranı oldukça düşüktür. Bu çalışmada mide adenokarsinomlarında HIF-1α doku ekspresyonunun prognostik öneminin değerlendirilmesi amaçlanmıştır.

Yöntem: Bu çalışmada, 114 mide adenokarsinom olgusunun gastrektomi materyallerinde immünohistokimyasal HIF-1a ekspresyonu incelenmiştir.

Bulgular: Olguların 24'ünde (%21,1) HIF-1α ekspresyonu saptanmıştır. HIF-1α ekspresyonu saptanan olgularda bir (p=0,02) ve beş yıllık (p=0,03) sağkalım daha yüksek bulunmuştur. Regresyon analizinde patolojik tümör evresi ileri tümörlerde de (pT3 ve pT4) ölüm riski 3,42 kat daha yüksek bulunmuştur. Yaş, cinsiyet, tümör boyutu, tümör yerleşimi, lenfovasküler ve perinöral invazyon, insan epidermal büyüme faktörü reseptörü 2 ekspresyonu ve diğer klinikopatolojik parametreler ile HIF-1α ekspresyonu ve sağkalım açısından istatistiksel olarak anlamlı sonuç bulunmamıştır.

Sonuç: Mide kanserlerinde spesifik prognostik belirleyicilerin ve yeni hedefe yönelik tedavi seçeneklerinin belirlenmesi çok önemlidir. Çelişkili bulgular olsa da; HIF-1α ekspresyonu pek çok malignitede olumsuz bir prognostik faktör olarak değer görmektedir ve özellikle HIF-1α/VEGF yolağında etkili olabilecek tedavi ajanları geliştirilmiştir. Oysa çalışmamızda HIF-1α ekspresyonu saptanan olgularda sağkalım oranı daha yüksek bulunmuştur. Gastrik karsinomlarda HIF-1α ekspresyonunun prognostik önemiyle ilgili, özellikle immünohistokimyasal değerlendirmenin standardizasyonu sonrası yapılacak daha çok çalışma ve veriye ihtiyaç vardır.

Anahtar Kelimeler: Mide, gastrik karsinom, HIF-1a, HER2

Introduction

Gastric cancer is the fifth most frequently occurring type of cancer world-wide. Despite its decreasing incidence, it still ranks fourth in terms of cancer-related mortality⁽¹⁾. Gastric cancer is a multifactorial disease and is primarily caused by *Helicobacter pylori (H. pylori)* infection, diet, alcohol consumption, smoking, Ebstein-Barr virus infection, and genetic factors are effective in its development^(2,3). Human epidermal growth factor receptor 2 (HER2), also known as "erythroblastosis oncogene B2 (ERBB2)", is a proto-oncogene encoded by the *ERBB2* gene located on chromosome 17⁽⁴⁾. HER2 overexpression is a common molecular abnormality in gastric cancers. Although its prognostic significance for gastric cancers is debatable, the detection of its overexpression in tumors has gained importance with the development of targeted therapies⁽⁵⁾.

Tumor hypoxia plays a key role in the progression of malignancy, and hypoxia-inducible factor-1 (HIF-1) acts as a master regulatory molecule in the adaptation of cells to changing levels of oxygen. HIF-1 is composed of α and β subunits of the basic helix-loop-helix transcription factor family. The β subunit is synthesized as a basic component, and its activity is controlled by an oxygen-independent mechanism. In contrast, the α subunit (HIF-1 α) is ubiquitinated and degraded under normoxic conditions and stabilized under hypoxia. Under hypoxic conditions, HIF-1 α activates many hypoxia-responsive elements, especially vascular endothelial growth factor, and stimulates pathways necessary for tumor progression^(6,7).

The aim of this study was to determine the possible prognostic significance of HIF-1 α in gastric cancer, to investigate its relationship with clinicopathologic parameters, and to contribute to the identification of HIF-1 α as a therapeutic target molecule.

Materials and Methods

A total of 114 cases of gastric adenocarcinoma diagnosed in the medical pathology laboratory of a research hospital between 2011 and 2014 were included in the study. Data related to age, sex, tumor location, tumor diameter, presence of lymph node metastasis, and TNM stage were obtained from pathology records. The presence of distant metastasis and survival data were retrieved from the hospital's electronic patient file system. Hematoxylin&eosin stained slide preparations of all cases were re-examined for tumor type, grade, pathological stage, and lymphovascular and perineural invasion (PNI). Immunohistochemically stained slides to assess HER2 expression were re-evaluated. Patients whose clinical and follow-up data were not available and whose tumor tissue material was insufficient for analysis were excluded from the study. The study was approved by the Local Ethics Committee of the University of Health Sciences Türkiye, İzmir Tepecik Education and Training Hospital (approval number: 2017/14-37, date: 11.12.2017). Informed consent was obtained from all patients prior to surgery to allow the use of the surgical materials obtained for scientific purposes.

Paraffin block, which is most suitable for immunohistochemistry (IHC) evaluation and best reflects the

characteristics of tumor tissue, was selected for the analysis. Next, paraffinized cylindrical tissue samples with a diameter of 2 mm were taken from the donor blocks by marking them first on the slide and then on the block. Multiple blocks (microarray blocks) were prepared using mapping and addressing techniques. From the prepared blocks, 4-m thick sections were placed on lysine-coated. One section was stained with hematoxylin and eosin and the other was manually stained with polyclonal HIF-1 α primary antibody (ATLAS, 1/300 dilution, catalog number: HPA001275). After deparaffinisation in an oven at 60 °C for 12 h, the sections were boiled in citrate solution for 20 minutes at 65 °C in a PT LINK device. Slides were allowed to cool in buffer solution for 5 min. Sections incubated with antibody for 1 h were manually stained using biotin-avidin peroxidase method (Invitrogen, Camarillo, CA, USA). Inflammatory cells in the sections also showed positive nuclear staining and were used as a positive internal control. HIF-1 α expression was not observed in every tumor or field of view. Nuclear or nucleocytoplasmic staining was considered as evidence of HIF-1 α expression⁽⁸⁾. Since HIF-1 α expression was heterogeneously distributed, no quantitative grading was performed, and expression was only evaluated as "present" or "absent" (Figure 1).

Statistical Analysis

Statistical analysis was performed using the IBM SPSS 22.0 statistical package program. P \leq 0.05 was accepted as the level of significance. For the comparison of quantitative data, the chi-square test was used. In the comparison of

quantitative parametric data independent groups, the t-test and non-parametric data Mann-Whitney U test were used. The non-parametric Kruskal-Wallis test was utilized for the comparison of more than 2 groups. For survival analysis, survival probabilities were tested with the Kaplan-Meier method, and the log-rank test was performed to determine whether there was a difference between survival probabilities. Cox regression analysis was then performed to identify factors affecting survival.

Results

The study population included 72 (63.2%) male and 42 (36.8%) female patients aged between 36 and 92 years, with a mean age at diagnosis of 63.8 years. Gastric adenocarcinomas were located in the cardia in 20 (17.5%), corpus in 54 (47.4%), and antrum/pylorus in 40 (35.1%) cases. The mean tumor size was 6.33 ±3.2 cm (range: 1-15 cm). According to the World Health Organization 2019 classification, the distribution of histological subtypes of tumors was as follows: poorly cohesive carcinoma (n=36; 31.6%), tubular (n=52; 45.6%), papillary (n=5; 4.4%), mucinous (n=12; 10.5%), and mixed (n=9; 7.9%) gastric adenocarcinomas. According to Lauren classification, the distribution of the histological types of the tumors was as follows: Diffuse type (n=36; 31.5%), intestinal type (n=69; 60.5%), and indeterminate type (n=9; 7%). According to pathologic TNM classification, adenocarcinomas were in stages pT4 (n=35; 30.7%), pT3 (n=66 cases; 57.9%), pT2 (n=6; 5.3%), and pT1b (n=7; 6.1%). Lymphovascular (n=74; 64.9%), perineural (n=68; 59.6%), and local lymph node metastasis



Figure 1. A) HIF-1α expression in tubular adenocarcinoma and B) In a diffuse (poorly cohesive) carcinoma specimen (DAB,200x) *HIF-1: Hypoxia-inducible factor-1*

(n=89; 78.1%) were detected in the indicated number of cases. The number of metastatic lymph nodes ranged from 1 to 44 (mean 7.5 \pm 8.8, median 7 lymph nodes). The study population consisted of patients with stage NO (n=25; 21.9%), N1 (n=14; 12.3%), N2 (n=29; 25.4%), N3a (n=24; 21.1%), and N3b (n=22; 19.3%) gastric adenocarcinoma. Distant organ

metastases were observed in 35 (30.7%) patients, and they were localized in the lungs (n=11), liver (n=15), peritoneum (n=7), and ovaries (n=2). Immunohistochemical HIF-1 α expression was detected in 24 of 114 patients (21.1%). The relationship between clinicopathological findings and HIF-1 α expression in patients is presented in Table 1.

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Table 1. Association between qualitative and quantitative findings of patients according to HIF-1A expression status					
Age (year)64.1±12.763.1±9.80.740Tumor diameter (cm)6.6±3.35.3±2.750.830Number of metastatic tymph nodes9.5±8.49.4±9.30.300Survival (months)23.6±22.13.6±22.4.30.101HIF1-A expressionAbsent N/%Present N/%700GenderMale Female55/61.11770.8 729.10.300Tumor typeIntestinal52/57.7117/0.8 710.80.300Tumor typeOthers6/6.73/12.40.300Tumor locationCardia Corpus15/16.65/20.9 729.10.700RER2 positivity (with IHC)Score 2 (++) Score 3 (+++)3/33.67/29.10.700Score 3 (++) Present3/36.61/4.1 729.10.700Ferenale3/33.32/8.30.300Lymphovascular invasionAbsent Present3/36.911/45.6Perineural invasionAbsent Present3/36.911/45.6Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present3/34.44/16.8Lymph node metastasesAbsent Present2/83.20.300Distant metastasesAbsent P	HIF1-A expression		Absent M/SD	Present M/SD	р	
Tumor diameter (cm) 6.643.3 5.342.75 0.830 Number of metastatic (ymph nodes 9.548.4 9.449.3 0.300 Survival (months) 23.6422.1 3.65±24.3 0.101 HIF1-A expression Male 55/61.1 177.0.8 0.300 Gender Male 55/61.1 177.0.8 0.300 Tumor type Intestinal 52/57.7 177.0.8 0.300 Others 6/6.7 312.4 0.100 Tumor location Cardia 15/16.6 5/20.9 0.700 Megative (-or+) 8/30.6 12/50 0.700 Antrum/pylori 33/36.6 12/50 0.700 Megative (-or+) 8/30.0 21/87.6 0.700 Score 2 (++) 6/6.6 1/4.1 0.710 Masent Present 37.3 2/8.3 0.602 Extensive necrosis Absent 8/97.8 21/87.6 Present 35/38.9 11/45.8 0.530 Qumph node metastases Absent 3/34.4 4/16.8 Present 35/61.1 13/54.2 0.530 Qumph node metastases Absent 3/34.4 4/16.8 0.300 Present 3/34.4 4/16.8 0	Age (year)		64.1±12.7	63.1±9.8	0.740	
Number of metastatic lymph nodes9.5±8.49.4±9.30.380Survival (months)>36.5±21.336.5±24.30.101HIF1-A expressionMale52.521.095.5±24.30.101GenderMale55.611.1177.0877.91.00.380Tumor typeIntestinal52.577.717.70.877.91.00.101Tumor typeOthers6/6.731.24.00.1010.101Tumor typeCardia15/16.652.99.07.91.00.101Tumor tocationCorpus42/46.612.50.07.60.0Tumor tocationScore 3 (++)81.90.021.87.67.10.0Metaster expression33.66.012.41.07.10.07.10.0Persent21.22.031.24.07.10.07.10.0Tumor locationAbsent81.97.821.87.67.10.0Metaster expressionAbsent34.37.76.75.07.10.0Persent56.61.313.75.47.30.07.30.0Tumph node metastaseAbsent31.98.013.54.23.30.0Pather expression31.34.013.54.23.30.03.30.0Distant metastasesAbsent51.61.113.77.03.30.0Distant metastasesAbsent51.61.113.77.03.30.0Distant metastasesAbsent51.61.113.77.03.30.0Distant metastasesAbsent51.61.113.61.03.30.0Distant metastasesAbsent51.61.113.61.03.30.	Tumor diameter (cm)		6.6±3.3	5.3±2.75	0.830	
Survival (months) </th <td colspan="2">Number of metastatic lymph nodes</td> <td>9.5±8.4</td> <td>9.4±9.3</td> <td>0.380</td>	Number of metastatic lymph nodes		9.5±8.4	9.4±9.3	0.380	
HIF1-A expressionAbsent N%Present N%Image NameGenderMale Female55/61.117/0.83.30Tumor typeIntestinal52/57.717/0.817/0.8Tumor typeDiffuse Others3/25.64/16.80.170Tumor typeCardia Corpus15/16.65/20.917/0.8Matum/pylori3/36.612/5017/0.817/0.8Megative (-or +)8/90.812/90.817/0.8Megative (-or +)8/90.812/80.817/0.8Marum/pylori3/36.61/4.10.700Score 2 (++)6/6.61/4.10.700Score 3 (+++)3/3.32/8.31/100Masent Present8/97.82/137.61/100Muphovascular invasionAbsent Present8/37.91/14.1Masent Present5/61.113/54.23/30Muph node metastasesAbsent Present1/20.81/10.8Muph node metastasesAbsent Present1/20.81/20.8Muph node metastasesLiver1/11.11/41.81/30.9Muph node metastasesLiver1/11.11/41.91/11.9Muph node metastasesLiver1/11.11/41.91/11.9Muph node metastasesSizent Present3/54.91/20.91/30.9Muph node metastasesAbsent Present1/11.11/41.91/11.9Muph nodeAbsent Present1/11.11/41.91/11.9Muph nodeJuph node <td colspan="2">Survival (months)</td> <td>23.6±22.1</td> <td>36.5±24.3</td> <td>0.101</td>	Survival (months)		23.6±22.1	36.5±24.3	0.101	
PenderMain FendeSolitionIntroductPartial SolitionInternationSolitionSolitionSolitionSolit	HIF1-A expression		Absent N/%	Present N/%		
Pende538.9729.10.330Tumor typeIntestinal5257.71770.8170.8Diffuse32/35.64/16.831.24Others6/6.731.2431.24Tumor locationCorpus4/46.612/50.9Antrum/pylori33/36.6729.170.9Antrum/pylori33/36.6729.170.9Megative (- or +)81/9021/87.670.9Score 2 (++)6/6.61/4.170.9Score 3 (++)3/3.321/87.670.9Penetro2/2.23/2.470.9Present2/2.23/2.470.9Present2/2.23/2.470.9Present5/6.1.311/45.870.9Present5/6.1.313/54.270.9Present7/20.011/45.870.9Present7/20.013/54.270.9Present7/20.011/45.870.9Present7/20.017/0.870.9Present3/34.44/16.870.9Present3/34.44/16.870.9Present13/44.014/1070.9Present13/44.014/1070.9Present13/14.014/1070.9Present13/44.014/1070.9Present13/44.014/1070.9Present13/44.014/1070.9Present13/44.014/1070.9Present13/1014/1014/10 <t< th=""><th rowspan="2">Gender</th><th>Male</th><th>55/61.1</th><th>17/70.8</th><th rowspan="2">0.380</th></t<>	Gender	Male	55/61.1	17/70.8	0.380	
Intestinal Diffuse Others5/57.7177.0.8A PTumor typeDiffuse Others3/3.54/16.80.170Arran Orpus10.6.73/2.43/2.40.170Tumor tootationCorpus Anturn/ptorin10.6.012/500.000Megative (- or +) Score 2 (++)3/3.672.9.10.000Megative (- or +) Score 2 (++)0.6.61/4.10.000Megative (- or +) Score 2 (++)0.6.21/4.10.000Megative (- or +) Score 2 (++)0.3.32/8.30.000Megative (- or +) Score 2 (++)0.3.32/8.30.000Megative (- or +) Score 2 (++)0.4.22/8.30.000Megative (- or +) Score 2 (++)0.4.22/8.30.000Megative (- or +) Score 2 (++)0.3.20.0000.000Megative (- or +) Score 2 (++)0.3.32/8.30.000Megative (- or +) Score 2 (++)0.4.20.0000.000Megative (- or +) Score 2 (++)0.3.20.0000.000Megative (- or +) Score 2 (++)0.0000.0000.000Megative (- or +) Score 2 (++)0.0000.0000.000Megative (- or +) Score 2 (++)0.0000.0000.000Megative (- or +) Score 2 (+)0.0000.0000.000Megative (- or +) Score 2 (+)0.0000.0000.000Megative (- or +) Score 2 (+)0.0000.0000.000Megative (- or +)0.000 <td< th=""><td>Female</td><td>35/38.9</td><td>7/29.1</td></td<>		Female	35/38.9	7/29.1		
Tumor typeDiffuse Others3/35.64/16.80.170Others6/6.73/12.43/12.43/12.4Tumor toationCardia15/16.65/20.9Approximate Approximate Antromyptori13/36.012/50Approximate A	Tumor type	Intestinal	52/57.7	17/70.8		
IndexOthers6/6.73/12.49Tumor locationCardia5/16.65/20.9ACorpus42/46.612/500.760Antrum/pylori3/36.67/29.10.760HER2 positivity (with IHC)Negative (- or +)8/90.81/4.10.700Score 2 (++)6/6.61/4.10.7000.700Extensive necrosisAbsent8/97.82/87.60.700Present2/2.23/12.40.6620.700Present2/2.23/12.40.6620.700Perheurat invasionAbsent3/37.76/250.700Present2/2.01/45.80.7000.700Perineurat invasionAbsent5/51.11/45.80.700Present2/801/70.80.7000.700Distant metastasesIver1/11.11/41.80.700Image in the present0.7101/11.11/41.10.700Image in the present0.7201/21.50.7000.700Image in the present1/11.11/41.10.7000.700Image in the present0.7550.83.00.7000.700Image in the present0.7550.7600.7000.700Image in the present0.7550.760.00.7000.700Image in the present0.7550.760.00.7000.700Image in the present0.7550.760.00.700.00.700Image in the present0.755.00.760.0 </th <td>Diffuse</td> <td>32/35.6</td> <td>4/16.8</td> <td>0.170</td>		Diffuse	32/35.6	4/16.8	0.170	
Randia15/16.05/20.9A 200A 200A 200A 200Tumor locationCorpus Antum/polori3/36.07/29.1A 200A 200HER2 positivity (with IHC)Negative (- or +) Score 2 (++) Score 2 (++) Score 3 (++)8/90.01/4.1A 200A 200Extensive necrosisAbsent Present8/97.82/80.02/80.0A 200Mphovascular invasionAbsent Present8/37.76/25 200.23/24.0A 200Perineural invasionAbsent Present3/38.91/45.8 200.23/34.0A 200Mph node metastasesAbsent Present1/200 2001/1001/200 200A 200Distant metastasesKasent Present1/201 2001/2011/200 200A 200Lung resent1/111/41 200 2001/200 2001/200 200A 200Atom of distant metastasesKasent Present1/200 200 2001/200 2001/200 200A 200Atom of distant metastasesKasent Present1/200 200 2001/200 2001/200 2001/200 2001/200 200Atom of distant metastasesKasent Present1/200 200 2001/200 2001/200 2001/200 2001/200 200Atom of distant metastasesKasent Present1/200 200 2001/200 2001/200 2001/200 2001/200 200Atom of distant metastaseKasent<		Others	6/6.7	3/12.4		
Tumor locationCorpus Antrum/pylori42/46.612/500.760Antrum/pylori33/36.67/29.17/29.1HER2 positivity (with IHC)Negative (- or +) Score 2 (++) Score 3 (++)81/9021/87.67.70Basent6/6.61/4.10.7107.707.70Extensive necrosisAbsent Present89/78.321/87.67.70Mphovascular invasionAbsent Present34/37.76/25 Score 3 (++)7.707.70Perineural invasionAbsent Present5/30.911/45.8 Score 3 (++)7.707.70Mphonde metastasesAbsent Present5/50.13/54.27.303.30Distant metastasesAbsent Present3/34.44/16.83.303.30Distant metastasesLiver Present3/34.44/16.83.303.30Location of distant metastasesLiver Present3/34.44/16.83.30Tumor stageLiver Present2/2.2Location of distant metastasesLiver Present2/2.1Tumor stageEarly Lung3/34.43/34.4Location of distant metastasesSolon Present2/2.2Location of distant metastasesEarly Present2/2.2Location of distant metastasesEarly Present2/2.2Location of distant metastasesEarly Present2/2.2Location of dista	Tumor location	Cardia	15/16.6	5/20.9		
IndexAntrum/pylori33/36.67/29.1HER2 positivity (with IHC)Negative (- or +) Score 2 (++)81/9021/87.6Score 2 (++) Score 3 (+++)3/3.32/8.30.710Extensive necrosisAbsent Present88/97.821/87.60.720Lymphovascular invasionAbsent Present34/37.76/25 Score 3 (++)0.720Perineural invasionAbsent Present35/38.911/45.8 Score 3 (++)0.720Perineural invasionAbsent Present35/38.911/45.8 Score 3 (++)0.730Perineural invasionAbsent Present18/20 72/807/29.1 17/0.80.300Lymph node metastasesSover 4 Present18/20 72/807/29.1 17/0.80.300Distant metastasesLiver Present10/11.11/4.1 41.680.300Lung Periton Ovary10/11.11/4.1 41.680.300Tumor stageEarly Lung Periton Ovary2/2.2-0.300Tumor stageEarly Lung Periton Ovary88.97.85/20.9 2.02.00.300Tumor stageEarly Lung Periton Ovary88.97.85/20.9 2.02.00.300Tumor stageEarly Lung88.97.85/20.9 2.02.00.300Tumor stageEarly Lung88.97.85/20.9 2.02.00.300Tumor stageEarly Lung88.97.85/20.9 2.02.00.300Tumor stageEarly Lung88.97.85/20.9 2.02.00.		Corpus	42/46.6	12/50	0.760	
HER2 positivity (with IHC)Negative (- or +) Score 2 (++) Score 3 (+++)B/902/87.6 (-4.1 (-3.3)D/10HER2 positivity (with IHC)Absent Present8/97.8 (-2.2)2/8.30.70Humphovascular invasionAbsent Present3/3.7 (-2.2)1/87.6 (-2.2)0.70Humphovascular invasionAbsent Present3/37.7 (-2.6)6/25 (-2.6)0.70Humphovascular invasionAbsent Present3/37.7 (-2.6)6/25 (-2.6)0.70Humph node metastasesAbsent Present3/38.9 (-2.6)1/45.8 (-2.6)0.70Humph node metastasesAbsent Present1/820 (-2.6)7/29.1 (-1.70.8)0.70Humph node metastasesAbsent Present5/965.5 (-2.6)2/83.2 (-2.6)0.30Humph node metastasesLiver Present1/11.11/4.1 (-2.6)0.30Humph node metastasesLiver Present1/11.01/4.1 (-2.6)0.30Humph node metastasesLiver Present1/41.5 (-2.6)1/4.1 (-2.6)0.30Humph node metastasesLiver Present1/41.5 (-2.6)1/4.1 (-2.6)0.30Humph node metastasesLiver Present1/41.5 (-2.6)1/4.1 (-2.6)0.30Humph node metastasesLiver Present1/41.5 (-2.6)1/4.1 (-2.6)0.30Humph node metastasesLiver Present1/41.5 (-2.6)1/41.9 (-2.6)0.30Humph node metastasesLiver Present1/41.5 		Antrum/pylori	33/36.6	7/29.1		
HER2 positivity (with IHC)Score 2 (++)6/6.61/4.10.710Score 3 (+++)3/3.32/8.30Score 3 (+++)8/97.82/8.30Extensive necrosisAbsent8/97.82/12.40Present2/2.23/12.400Lymphovascular invasionAbsent9/37.76/2500Perineural invasionAbsent5/62.311/45.80.300Persent55/61.113/54.20.3000.300Lymph node metastasesAbsent18/207/29.10.300Present72/807/29.10.3000.300Distant metastasesAbsent59/65.520/83.20.300Present10/11.11/4.10.1010.101Lung14/15.51/4.10.4100.410Periton5/5.52/8.30.400Ovary2/2.2-0.101Tumor stageEarly Late8/8.95/20.90.101	HER2 positivity (with IHC)	Negative (- or +)	81/90	21/87.6		
IdealScore 3 (+++)3/3.32/8.31Extensive necrosisAbsent Present8/97.82/1.43/1.4Lymphovascular invasionAbsent Present3/3.76/253/1.4Perineural invasionAbsent Present3/3.8.911/45.83/3.9Lymph node metastasesAbsent Present3/3.911/45.83/3.9Distant metastasesAbsent Present18/207/29.13/3.9Distant metastasesAbsent Present13/4.41/41.83/3.4Lump Present3/3.41/41.83/3.43/3.4Lump Present1/11.11/4.13/4.13/3.4Lump Present1/15.51/4.13/3.43/3.4Lump Present2/2.22/3.33/3.43/3.4Lung Periton Ovary2/2.12/3.33/3.43/3.4Lump Periton Ovary2/2.22/3.33/3.4Lump Periton Ovary2/2.22/3.33/3.4Lump Periton Ovary2/2.22/3.33/3.4Lump Periton Ovary2/2.22/3.33/3.4Lump Periton Ovary3/3.43/3.43/3.3Lump Periton Ovary3/3.43/3.43/3.4Lump Periton Ovary3/3.43/3.43/3.4Lump Periton Ovary3/3.43/3.43/3.4Lump Periton Ovary3/3.43/3.43/3.4Lump Periton Ovary3/3.43/3.4 <td< th=""><td>Score 2 (++)</td><td>6/6.6</td><td>1/4.1</td><td>0.710</td></td<>		Score 2 (++)	6/6.6	1/4.1	0.710	
Absent88/97.821/87.6 ∂_{002} Present2/2.23/12.4 ∂_{002} Lymphovascular invasionAbsent Present3/37.7 $\delta/25.$ ∂_{17} Perineural invasionAbsent Present35/38.9 $11/45.8$ ∂_{13} Lymph node metastasesAbsent Present18/20 $13/54.2$ ∂_{13} Differentiation of distant metastasesAbsent Present $18/20$ $17/0.8$ ∂_{13} Lumph node metastasesAbsent Present $13/34.4$ 14.13 ∂_{13} Differentiation of distant metastasesLiver Lung Presint 101.11 14.12 ∂_{13} Lumph nodeLiver Present 101.12 14.13 ∂_{13} Differentiation of distant metastasesLiver Lung Presint 101.12 14.12 ∂_{13} Lumph nodeLiver Present 101.12 14.12 ∂_{13} Lumph nodeLiver Present 101.12 14.12 ∂_{13} Lungh node 101.12 14.12 14.12 ∂_{13} Lungh node 12.22 12.12 12.12 12.12 Lungh node 12.22 12.12 12.12 12.12 Lungh node 12.12 12.12 12.12 12.12 Lumph node 12.12 12.12 12.12 12.12 Lumph node 12.12 12.12 12.12 12.12 Lumph node 12.12 12.12 12.12 12.12 Lumph node 12.12 12.12		Score 3 (+++)	3/3.3	2/8.3		
Present 2/2.2 3/12.4 0.002 Lymphovascular invasion Absent Present 34/37.7 6/25 0.240 Perineural invasion Absent Present 55/62.3 18/75 0.240 Lymph node metastases Absent Present 55/61.1 13/54.2 0.530 Lymph node metastases Absent Present 18/20 7/29.1 0.330 Distant metastases Absent Present 59/65.5 20/83.2 0.330 Lung Present 10/11.1 1/4.1 0.130 Lung Periton of distant metastases Liver 10/11.1 1/4.1 0.918 Lung Periton Ovary 2/2.2 - 0.918 0.918 Tumor stage Early Late 8/8.9 5/20.9 0.100	Extensive necrosis	Absent	88/97.8	21/87.6	0.062	
Lymphovascular invasion Absent Present 34/37.7 6/25 32-30 Perineural invasion Absent Present 35/38.9 13/45.0 3-30 Lymph node metastases Absent Present 13/54.2 3-30 Datamathemetastases Absent Present 18/20 7/29.1 3-30 Datamathemetastases Absent Present 19/65.5 20/83.2 3-30 Datamathemetastases Signant 11/45.5 20/83.2 3-30 Liner 10/11.1 14/1.0 3-30 3-30 Liner 10/11.1 14/1.1 3-30 3-30 Liner 10/11.1 14/1.1 3-30 3-30 Liner 10/11.1 14/1.1 3-30 3-30 Liner 10/11.1 14/1.1 3-30 3-30 Liner 10/11.1 14/1.1 3-30 3-30 Liner 10/11.1 10/11.1 10/11.1 3-30 Liner 10/11.1 10/11.1 10/11.1 3-30 Liner<		Present	2/2.2	3/12.4		
Present 56/62.3 18/75 0.210 Perineural invasion Absent Present 35/38.9 11/45.8 0.530 Lymph node metastases Absent Present 18/20 7/29.1 0.330 Distant metastases Absent Present 59/65.5 20/83.2 0.130 Distant metastases Present 31/34.4 4/16.8 0.130 Lung 14/15.5 1/4.1 0.908.2 0.908.2 Periton 5/5.5 2/8.3 0.908.2 Ovary 2/2.2 - - Tumor stage Early Late 8/8.9 5/20.9 0.100	Lymphovascular invasion	Absent	34/37.7	6/25	0.240	
Perineural invasionAbsent35/38.911/45.8 -230 Present5/61.11/54.20.300Lymph node metastasesAbsent18/207/29.1 -330 Present72/801/70.80.300Distant metastasesAbsent59/65.520/83.2 -300 Present10/11.11/41.9 -300 Lung14/15.51/41.0 -400 -900 Pretron5/55.52/83.0 -200 -900 Tumor stageEarly Late8/8.95/20.9 -1000		Present	56/62.3	18/75		
Present 55/61.1 13/54.2 0.000 Lymph node metastases Absent Present 18/20 7/29.1 0.330 Distant metastases Absent Present 59/65.5 20/83.2 0.130 Lucation of distant metastases Liver 10/11.1 1/4.1 0.918 Periton Ovary 2/2.2 2/8.3 0.918 Tumor stage Early Late 8/8.9 5/20.9 0.100	Perineural invasion	Absent	35/38.9	11/45.8	0.530	
Lymph node metastases Absent Present 18/20 7/29.1 3030 Distant metastases Absent Present 59/65.5 20/83.2 3.130 Distant metastases Fresent 31/34.4 4/16.8 3.130 Location of distant metastases Liver 10/11.1 1/4.1 4.14 Long 14/15.5 1/4.1 4.14 4.14 Periton 5/5.5 2/8.3 4.14 Ovary 2/2.2 - - 9.14 Tumor stage Early Late 8/8.9 5/20.9 9.10		Present	55/61.1	13/54.2		
Present 72/80 17/70.8 0.000 Distant metastases Absent Present 59/65.5 20/83.2 0.130 Liver 10/11.1 1/4.1 4/16.8 0.130 Periton 5/5.5 2/8.3 0.130 Tumor stage Early Late 8/8.9 5/20.9 0.100	Lymph node metastases	Absent	18/20	7/29.1	0.330	
Absent 59/65.5 20/83.2 3.130 Present 31/34.4 4/16.8 3.130 Location of distant metastases Liver 10/11.1 1/4.1 Apple Periton 5/5.5 2/8.3 3.130 Ovary 2/2.2 - - Tumor stage Early 8/8.9 5/20.9 Late 8/20.11 10/70.1 -		Present	72/80	17/70.8		
Present 31/34.4 4/16.8 0.130 Liver 10/11.1 1/4.1 Jappen 14/15.5 1/4.1 Lung 14/15.5 1/4.1 Jappen 14/15.5 Jappen 14/15.5 Veriton 5/5.5 2/8.3 Jappen 14/15.5 Jappen 14/15.5 Tumor stage Early 8/8.9 5/20.9 Jappen 14/15.5	Distant metastases	Absent	59/65.5	20/83.2	0.130	
Liver 10/11.1 1/4.1 Lung 1/4.15.5 1/4.1 1/4.1 Periton 5/5.5 2/8.3 0.918 Ovary 2/2.2 - 0.918 Tumor stage Early 8/8.9 5/20.9 0.100		Present	31/34.4	4/16.8		
Lung 14/15.5 14/1.1	Location of distant metastases	Liver	10/11.1	1/4.1	0.918	
Periton 5/5.5 2/8.3 000000000000000000000000000000000000		Lung	14/15.5	1/4.1		
Ovary 2/2.2 - - Funder stage Early 8/8.9 5/20.9 - Late 8/9/1.1 19/79.1 - -		Periton	5/5.5	2/8.3		
Early 8/8.9 5/20.9 0.100 Late 82/91.1 19/79.1		Ovary	2/2.2	-		
Late 82/91.1 19/79.1	Tumor stage	Early	8/8.9	5/20.9	0.100	
		Late	82/91.1	19/79.1		
Deceased 67/74.4 13/54.2 0.054	Survival status	Deceased	67/74.4	13/54.2	0.054	
Survived 23/25.6 11/45.8		Survived	23/25.6	11/45.8		

HER2 IHC scores were 0 or 1+ in 102 (89.5%) cases, and both groups were considered HER2-negative. IHC scores of 2+ and 3+ were detected in 6.1% (n=7) and 4.4% (n=5) of the cases, respectively. While HIF-1 α expression was observed in 3 (25%) HER2- positive, but in 21 (20.58%) HER2- negative cases. There was no statistically significant correlation between HER2- negative and positive groups and HIF-1 α expression (p=0.71).Similarly, there were no statistically significant differences in HIF-1 α expression according to most clinicopathological features, such as sex (p=0.38), age (p=0.74), tumor location (p=0.76), histological type of tumors (p=0.17), presence of lymph node metastasis (p=0.33), pathological tumor stage (p=0.10), tumor size (p=0.83), lymphovascular invasion (LVI) (p=0.24), PNI (p=0.53), presence of extensive tumor necrosis (p=0.062), and presence of distant metastases (p=0.13). Although there was no statistical relationship between the presence of HIF-1 expression and the mean survival time and survival status, the difference was significant when compared with the median survival time. The reason for this can be explained by the fact that the survival times of the patients were in a very wide range, and the standard deviation was large. On the other hand, the median survival times were 41.4 and 15.4 months in HIF-1 α positive, and negative cases, respectively, and a statistically significant (p=0.03) difference was detected between both groups in terms of HIF-1 α staining status. Contrary to most studies in the literature, the survival time was longer in our patients with HIF-1 α expressing tumors (Figure 2). In terms of HIF-1 α staining status, the 1- and 5-year survival rates in HIF-1 α positive, and negative groups were 45.8% vs. 36.9% and 25.6% vs. 22.3%, respectively, with statistically significant intergroup differences (p=0.02 vs. 0.03).

Discussion

The incidence of gastric cancer significantly increases with age. Most patients are diagnosed between the ages of 60 and 80 years. Gastric cancers are rarely diagnosed in patients aged 45 years and are defined as "early-onset gastric cancer". It is believed that early-onset cases have different clinicopathological characteristics and develop in different models of carcinogenesis⁽⁹⁾. The mean age at diagnosis in our study population was 63.89 years, which is consistent with the literature findings. Only 7% of our patients were under 45 years of age at the time of diagnosis.

Gastric cancer is twice as common in men as in women. In addition, they are the fourth and fifth most common causes of cancer-related deaths in men and women, respectively⁽¹⁻³⁾. The gender distribution of the study population was consistent with the literature findings. The process of gastric carcinogenesis is multifactorial, and both environmental and genetic factors play a role in the development of gastric cancers⁽⁹⁾. Approximately 89% of all gastric tumors are associated with *H. pylori* infection⁽²⁾.

Although gastric tumors seem to represent a single disease state, they can be considered as two entities "cardia" and "non-cardia" gastric cancers based especially on their widely different etiopathogenesis. Although HP infection, low socio-economic status, and dietary factors are blamed for the development of non-cardia gastric cancers, obesity and gastroesophageal reflux disease are believed to play a role in the etiology of gastric cardia cancers. Age, male sex, family history, smoking, and radiation exposure are common risk factors for tumors located in both regions^(2,5,10-12). Gastric cancer localization frequently varies according to the geographic region in which the patient lives. Although distally localized tumors i.e., in the corpus, antrum, and pylorus) constitute the majority of cases in the geographic regions where gastric cancer is endemic, tumors localized in the cardia and fundus are slightly more common in other geographic regions⁽¹²⁾. It is known that the prognosis of gastric cardia cancer is worse than that of distal gastric tumors because they are usually diagnosed at an advanced stage⁽⁹⁾. Although 20 (17.5%) cases of gastric carcinomas included





in our study were located in the cardia/fundus, 94 (82.5%) were located in the distal stomach. A statistically significant difference was not detected in survival times between patients with gastric tumors of different localizations. More than 90% of gastric cancers have adenocarcinoma morphology, and the most common histologic type is tubular adenocarcinoma according to the World Health Organization classification. When the Lauren classification is taken into consideration, intestinal-type gastric carcinoma was more common in the past, whereas in recent years, especially in some countries, the incidence rates of diffuse and intestinal carcinoma seem to be close to each other⁽²⁾. Similarly, 45.6% of our cases had tubular adenocarcinoma morphology, followed by poorly cohesive carcinomas with a frequency of 31.6%. According to Lauren classification, most of the cases were intestinal type carcinomas (60.5%).

TNM staging alone is the most important prognostic factor of gastric cancer. Although 5-year survival is >90% in patients with pT1 tumors without lymph node metastasis, this rate decreases to 30% in those with pT3 tumors⁽²⁾. Our patients had pT1 and pT2 (n=13; 11.4%), pT3 (n=66; 57.9%), and pT4 (n=35; 30.7%) adenocarcinomas. When pT1 and pT2 cases were included in the early-stage gastric adenocarcinoma group and pT3 and pT4 cases in the late-stage gastric adenocarcinoma group, the median survival was 55 months in patients with pT1 and pT2 tumors, whereas it was 27.9 months in those with pT3 and pT4 tumors, with a statistically significant difference between groups (p=0.006).

The lymph node status is not only important in determining the stage of gastric cancer but also in indicating the need for adjuvant treatment. Recent studies have shown that "metastatic lymph node ratio", defined as the ratio of metastatic lymph nodes to total resected lymph nodes, may be an independent prognostic factor for gastric cancers⁽¹³⁾. Our study population of 114 patients were included in stages N0 (n=25; 21.9%), N1 (n=14; 12.3%), N2 (n=29; 25.4%), N3a (n=26; 21.1%), and N3b (n=22; 19.3%) based on the number of metastatic lymph nodes. Although the median survival time of patients without lymph node metastasis was significantly longer, the intergroup difference was not statistically significant.

Despite the fact that LVI is one of the most important factors in the development of lymph node metastasis in gastric carcinomas, data on its effect on survival as an independent factor remain controversial⁽¹⁴⁾. LVI was observed in 52 (31.9%) of 114 patients. In terms of survival, the median survival time was slightly longer in patients without LVI (20.1 months) than in those with LVI (18 months). However, the difference between the two groups was not statistically significant. Although PNI can predict recurrence in gastric cancers, there is not enough data on its prognostic value. Deng et al.⁽¹⁵⁾ reported that PNI can be considered an independent prognostic factor in a meta-analysis of 24 studies including 30,590 patients who underwent curative gastrectomy. In the present study, PNI was found in 43 patients (25.9%). The median survival time was 17.9 months in patients with PNI and 24.7 months in those without. The difference between the two groups was not statistically significant in terms of median survival time.

Approximately 40% of gastric cancers are metastatic at the time of diagnosis, and the median survival for untreated metastatic gastric cancers is 4 months, whereas the 5-year survival is 3-6%⁽¹⁶⁾. Metastases commonly spread to the lungs and liver via hematogenous routes. Distant metastasis was found in 35 (30.7%) patients. In parallel with the literature, these metastases were most commonly observed in the liver, lungs, peritoneum, and ovaries. The median survival times were 24.2 months in patients without distant metastases and 14.7 months in patients without. Although this intergroup difference was remarkable and consistent with the literature, it was not statistically significant.

One of the most important molecules for targeted gastric cancer treatment is HER2. HER2 participates in cell growth and differentiation. The association between HER2 positivity and poor prognosis, especially in breast cancer, has paved the way for the study of HER2 overexpression in gastric cancer. Overexpression of HER2 is found in approximately 10-30% of gastric cancers^(2,5). HER2 was found to be associated with male sex, intestinal type cancer, and moderate/good cell differentiation in gastric cancers⁽⁵⁾. The total gene expression analysis study conducted by targeting HER2 revealed that trastuzumab, a HER2 monoclonal antibody, may contribute favorably to survival in the treatment of gastric cancer⁽¹⁴⁾. The relationship between HER2 positivity and prognosis remains controversial^(2,5). HER2 was evaluated immunohistochemically in all specimens from the 114 patients included in our study. In 102 (89.5%) patients, the HER2 IHC scores were 0 and 1+, indicating HER2-negativity. HER2 IHC scores of 2 (n=7; 6.1%) and 3 (n=5; 4.4%) were designated for the indicated number of patients. We were able to access the data of 99 patients whose HER2/neu gene expression status was evaluated using the fluorescence in situ hybridization (FISH) method. HER2 overexpression was observed in 10 of 99 cases (10.1%). The findings obtained using both methods were consistent with the literature. The median survival time was 3.6 months in patients with HER2 overexpression (score 3), 18 months in patients with HER2 IHC scores of 2, and 22.1 months in HER2-negative patients. Similarly, median survival times were 11.4 and 22.9 months in patients with and without HER2 overexpression when the FISH method was used. The results obtained by both methods were guite similar. The median survival of patients with HER2 overexpression was markedly shorter, but no statistically significant difference was observed between both groups. Studies examining the relationship between HER2 and HIF-1 α have shown that HER2 overexpression stimulates HIF-1 α -dependent gene transcription not directly but in combination with other tumor-specific genetic and physiological changes⁽⁶⁾. It should be kept in mind that the fact that all HER2-positive patients in our study received targeted therapy may have led to the lack of a statistically significant difference in survival between groups with and without HER2 overexpression.

In mammalian cells, it is essential to maintain oxygen homeostasis to meet energy needs and sustain aerobic metabolism. In rapidly proliferating cancer cells, increased oxygen consumption and decreased oxygen transport and diffusion lead to hypoxia. Inadequate and chaotic vascularization also leads to severe deterioration of the oxygen balance in tumor cells^(6,7). It has been shown that HIF-1 α plays an important role in the adaptation of tumor cells to these changes in oxygen concentrations and thus in tumor progression. HIF-1 α realizes this adaptation by regulating many genes involved in the angiogenesis, glucose metabolism, cell proliferation, invasion, and metastasis pathways^(17,18). In the literature, HIF-1 α overexpression has been reported in many organ cancers, including colorectal, breast, lung, ovarian, and pancreatic cancers. In most of these malignancies, HIF-1 α is generally associated with poor prognosis⁽¹⁹⁾. Since gastric cancers still rank high in cancer mortality and are usually diagnosed at an advanced stage, the search for new treatment modalities and agents that will contribute to survival continues. HIF-1 α is becoming one of the popular targets in the approach to gastric cancers^(20,21).

Despite the advocacy of opposing views, in many studies, HIF-1 α expression in a wide range of malignant tumor tissues, including gastric adenocarcinomas, has been associated with low survival and adverse clinicopathological factors⁽²⁰⁻²³⁾. In our study, the 1-year survival rates were

45.8% in HIF-1 α positive, and 25.6% in the HIF-1 α negative group with a statistically significant intergroup difference (p=0.02). Contrary to most studies cited in the literature, the 5-year survival rates were 36.9% and 22.3% in the HIF-1 α positive, and negative groups with a statistically significant difference between groups. The existence of contradictory and sometimes conflicting results in the literature may be related to the fact that HIF-1 α is a complex molecule that may have both apoptosis-inducing and inhibitory effects in cell metabolism, as well as stimulating or inhibiting cell proliferation^(6,7). In addition, pathways involved in tumor progression and induced pathways may be differentially stimulated by HIF-1 α . It is thought that the level of hypoxia, presence of an oncogene, or homologs such as HIF-2 α and HIF-3 α may also be effective in the regulation of these pathways, which may affect HIF-1 α expression levels in tumors⁽¹¹⁾. In addition, interobserver differences in the evaluation of HIF-1 α immunohistochemistry should be considered when analyzing different results. All of these data support the argument that further studies are needed to accept HIF-1 α as a target molecule for determining prognosis and targeted therapies⁽²⁴⁾.

While HIF-1 α expression was detected in 60% of the cases with extensive tumor necrosis, whereas 19.3% of the cases without necrosis were HIF-1 α positive. Considering the role of HIF-1 α in hypoxic conditions, this finding was considered to be compatible with the nature of the molecule, and the fact that this finding was not statistically significant may be related to the small number of cases with necrosis included in our study. In the regression analysis, the risk of death was 3.42 times higher in advanced tumors than in early-stage tumors.

Study Limitations

Our study has several limitations. The most important of these limitations is that the tissues used for immunohistochemical staining were obtained by the tissue microarray method, which suggests that our results may be affected by tumor heterogeneity. Second, there is no specific standardization for the immunohistochemical evaluation of HIF-1 α expression. For example, Rohwer et al.^(B) not only performed a quantitative evaluation of HIF-1 α expression in tumor cells but also divided them into groups to perform a qualitative evaluation, perhaps to eliminate the handicaps of heterogeneous staining. Because very small tumor areas were evaluated in our study, it was not possible to create ordinal groups. In addition, nuclear or nucleocytoplasmic staining was used as the basis in the studies we referenced in our study. There is no consensus on any cut-off value for HIF- 1α expression level. Under these conditions, comparing data obtained from different sources will not yield optimal results. Finally, the fact that patients who received neoadjuvant treatment were not allocated into different groups during patient selection may be a factor that may affect both HIF- 1α expression and survival.

Conclusion

As a result, $HIF-1\alpha$ and cancer-related studies have shown that $HIF-1\alpha$ expression can have positive effects on cancer treatment and prognosis. $HIF-1\alpha$ can also be used to improve survival in patients with gastric cancer, which is one of the most frequently seen and aggressive cancers. Therefore, new and comprehensive studies are needed in this regard.

Ethics

Ethics Committee Approval: The study was approved by the Local Ethics Committee of the University of Health Sciences Türkiye, İzmir Tepecik Education and Training Hospital (approval number: 2017/14-37, date: 11.12.2017).

Informed Consent: Informed consent was obtained from all patients prior to surgery to allow the use of the surgical materials obtained for scientific purposes.

Acknowledgments

*An oral presentation titled the relationship of immunohistochemical HIF-1 α expression to clinicopathological parameters in gastric carcinomas was performed at the 27th National Pathology Congress held in Antalya on 15-18 November 2017.

*This study titled "Evaluation of Immunohistochemical HIF-1 α Expression in Gastric Adenocarcinomas in Terms of Clinicopathological Parameters" is an article prepared from Talya Akata's specialty thesis at University of Health Sciences Türkiye, İzmir Tepecik Education and Training Hospital.

*The English translation and editing of the article were done by Gökhan Kazancı.

Footnotes

Authorship Contributions

Surgical and Medical Practices: T.A., G.D., P.Ö., Y.K., S.A., Concept: T.A., G.D., Design: T.A., G.D., Data Collection or Processing: T.A., G.D., P.Ö., Y.K., Analysis or Interpretation: T.A.,

G.D., P.Ö., Y.K., S.A., Literature Search: T.A., G.D., P.Ö., Y.K., Writing: T.A., G.D., P.Ö., S.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support

References

- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
- Kayapinar AK, Solakoglu D, Bas K, et al. Relationship of prognostic factors in stomach cancer with Helicobacter pylori: a retrospective study. Acta Gastroenterol Belg. 2022;85:35-45.
- 3. Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Curr Treat Options Oncol. 2020;21:70.
- 4. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22:4619-25.
- Usturalı Keskin E, Diniz G, Usturalı Mut AN, et al. Evaluation of the relationship between ARID1A expression with clinicopathologic parameters in gastric carcinomas. TERH. 2019;29:273-9.
- 6. Ajduković J. HIF-1--a big chapter in the cancer tale. Exp Oncol. 2016;38:9-12.
- 7. Griffiths EA, Pritchard SA, Valentine HR, et al. Hypoxia-inducible factorl α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer. 2007;96:95-103.
- Rohwer N, Lobitz S, Daskalow K, et al. HIF-1 alpha determines the metastatic potential of gastric cancer cells. Br J Cancer. 2009;100:772-81.
- 9. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:335-49.e15.
- 10. Sumiyama K. Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric Cancer. 2017;20:20-7.
- Mizokami K, Kakeji Y, Oda S, et al. Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas. J Surg Oncol. 2006;94:149-54.
- 12. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21.
- Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420-9.
- 14. Mei D, Zhao B, Zhang J, et al. Impact of lymphovascular invasion on survival outcome in patients with gastric cancer. Am J Clin Pathol. 2020;153:833-41.
- Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: A systematic review and meta-analysis. PLoS One. 2014;9:e88907.
- 16. Tan HL, Chia CS, Tan GHC, et al. Metastatic gastric cancer: Does the site of metastasis make a difference? Asia Pac J Clin Oncol. 2019;15:10-7.
- 17. Soni S, Padwad YS. HIF-1 in cancer therapy: two-decade long story of a transcription factor. Acta Oncol. 2017;56:503-15.
- Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016;138:1058-66.

- Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010;176:2292-301.
- 20. Chen L, Shi Y, Yuan J, et al. HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients' post-gastrectomy. PLoS One. 2014;9:1-12.
- Lin S, Ma R, Zheng XY, et al. Meta-analysis of immunohistochemical expression of hypoxia-inducible factor-1α as a prognostic role in gastric cancer. World J Gastroenterol. 2014;20:1107-13.
- 22. Kim SE, Shim KN, Jung SA, Yoo K, Joo HL. The clinicopathological significance of tissue levels of hypoxia-inducible factor- 1α and vascular endothelial growth factor in gastric cancer. Gut Liver. 2009;3:88-94.
- 23. Zhang J, Wu Y, Lin YH, et al. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer. World J Gastroenterol. 2018;24:2381-91.
- Yan Z, Liu K, Xu P, et al. ACLY promotes gastric tumorigenesis and accelerates peritoneal metastasis of gastric cancer regulated by HIF-1A. Cell Cycle. 2023t;22:2288-301.